Regulatory Disclosure - Quarter 1 2022 (Unaudited)

Notice to Readers

The information contained in this Supplement has not been audited or independently verified. Accordingly readers are cautioned that this Supplement may not be appropriate for their purposes.

A. Basel III Pillar 3 Public Capital Disclosure

Modified Capital Disclosure		All-in
		(Thousands)
1	Directly issued qualifying common share capital (and equivalent for	37,000
	non-joint stock companies) plus related stock surplus	
2	Retained earnings	44.236
3	Accumulated other comprehensive income (and other reserves)	
4	Directly issued capital subject to phase out from CET1 (only	Nil
	applicable to non-joint stock companies)	
5	Common share capital issued by subsidiaries and held by third parties	Nil
	(amount allowed in group CET1)	
6	Common Equity Tier 1 capital before regulatory adjustments	81.236
	Common Equity Tier 1 capital: regulatory adjustments	
28	Total regulatory adjustments to Common Equity Tier 1	425
29	Common Equity Tier 1 capital (CET1)	80,811
	Additional Tier 1 capital: instruments	
30	Directly issued qualifying Additional Tier 1 instruments plus related	Nil
	stock surplus	
31	of which: classified as equity under applicable accounting standards	Nil
32	of which: classified as liabilities under applicable accounting	Nil
33	standards Directly issued capital instruments subject to phase out from	Nil
33	Additional Tier 1	IN11
34	Additional Tier 1 instruments (and CET1 instruments not included in row 5) issued by subsidiaries and held by third parties (amount allowed in group AT1)	Nil
35	of which: instruments issued by subsidiaries subject to phase out	Nil
36	Additional Tier 1 capital before regulatory adjustments	
	Additional Tier 1 capital: regulatory adjustments	
43	Total regulatory adjustments to Additional Tier 1 capital	Nil
44	Additional Tier 1 capital (AT1)	Nil
45	Tier 1 capital (T1 = CET1 + AT1)	80,811
	Tier 2 capital: instruments and allowances	
46	Directly issued qualifying Tier 2 instruments plus related stock surplus	Nil

Modified Capital Disclosure		All-in
		(Thousands)
47	Directly issued capital instruments subject to phase out from Tier 2	Nil
48	Tier 2 instruments (and CET1 and AT1 instruments not included in	Nil
	rows 5 or 34) issued by subsidiaries and held by third parties (amount	
	allowed in group Tier 2)	
49	of which: instruments issued by subsidiaries subject to phase out	Nil
50	Collective allowances	Nil
51	Tier 2 capital before regulatory adjustments	Nil
	Tier 2 capital: regulatory adjustments	
57	Total regulatory adjustments to Tier 2 capital	Nil
58	Tier 2 capital (T2)	Nil
59	Total capital $(TC = T1 + T2)$	80,811
60	Total risk weighted assets	347,192
	Capital ratios	
61	Common Equity Tier 1 (as a percentage of risk weighted assets)	23.28%
62	Tier 1 (as a percentage of risk weighted assets)	23.28%
63	Total capital (as a percentage of risk weighted assets)	23.28%
	OSFI all-in target	
69	Common Equity Tier 1 capital all-in target ratio	7.0%
70	Tier 1 capital all-in target ratio	8.5%
71	Target capital all-in target ratio	10.5%
	Capital instruments subject to phase-out arrangements	
	(only applicable between 1 Jan 2013 and 1 Jan 2022)	•
80	Current cap on CET1 instruments subject to phase out arrangements	Nil
81	Amount excluded from CET1 due to cap (excess over cap after	Nil
	redemptions and maturities)	
82	Current cap on AT1 instruments subject to phase out arrangements	Nil
83	Amount excluded from AT1 due to cap (excess over cap after	Nil
	redemptions and maturities)	
84	Current cap on T2 instruments subject to phase out arrangements	Nil
85	Amount excluded from T2 due to cap (excess over cap after	Nil
	redemptions and maturities)	

B. Basel III Leverage Ratio Disclosure for Non-DSIBs "All-In Basis"

	Item	Leverage Ratio Framework (Thousands)			
	On-balance sheet exposures				
1	On-balance sheet items (excluding derivatives, SFTs and grandfathered securitization exposures but including collateral)	472,504			

	Leverage Ratio Framework (Thousands)			
2	Gross-up for derivatives collateral provided where deducted from			
	balance sheet assets pursuant to the operative accounting framework (IFRS)			
3	(Deductions of receivables assets for cash variation margin provided in derivative transactions)			
4	(Asset amounts deducted in determining Tier 1 capital)	(425)		
5	Total on-balance sheet exposures (excluding derivatives and SFTs) (sum of lines 1 to 4)	472,079		
	Derivative exposures			
6	Replacement cost associated with all derivative transactions	1,539		
7	Add-on amounts for potential future exposure associated with all derivative transactions			
8	(Exempted central counterparty-leg of client cleared trade exposures)			
9	Adjusted effective notional amount of written credit derivatives			
10	(Adjusted effective notional offsets and add-on deductions for written credit derivatives)			
11	Total derivative exposures (sum of lines 6 to 10)	1,539		
Securities financing transaction exposures				
12	Gross SFT assets recognised for accounting purposes (with no recognition of netting), after adjusting for sale accounting transactions			
13	(Netted amounts of cash payables and cash receivables of gross SFT assets)			
14	Counterparty credit risk (CCR) exposure for SFTs			
15	Agent transaction exposures			
16	Total securities financing transaction exposures (sum of lines 12 to 15)			
Other off-balance sheet exposures				
17	Off-balance sheet exposure at gross notional amount	26,578		
18	(Adjustments for conversion to credit equivalent amounts)	(13,497)		
19	Off-balance sheet items (sum of lines 17 and 18)	13,081		
	Capital and Total Exposures			
20	Tier 1 capital	80,811		
21	Total Exposures (sum of lines 5, 11, 16 and 19)	486,699		
Leverage Ratios				

Item	Leverage Ratio Framework (Thousands)
Basel III leverage ratio	16.60%

C. Residential Mortgages Public Disclosure

I. Amount of the total Residential Mortgages and Home Equity Lines of Credit (HELOC)

As at March 31, 2022 (in thousands of Canadian dollars)

	Residential Mortgage		HELOC		
Region	Uninsured	Total	Uninsured	Total	
British Columbia	130,676	130,676	4,015	4,015	
Ontario	19,272	19,272		Nil	
Other Jurisdictions		Nil		Nil	
Total	149,949	149,949	4,015	4,015	

All Residential Mortgages and HELOCs are uninsured.

II. Residential Mortgage percentages by Amortization Periods

As at March 31, 2022

Amortization Period (Years)	1 ~ 19	20 ~ 25	26 ~ 30	Total
Canada	0%	9%	91%	100%
Other Jurisdictions				Nil
Total	0%	9%	91%	100%

III. Average Loan to Value (LTV) ratio for newly originated and acquired uninsured residential mortgages and HELOCs at the end of each period.

Three months period ending March 31, 2022

Region	Average LTV
British Columbia	59%
Ontario	Nil
Other Jurisdictions	Nil
Total	59%

IV. Potential impact on residential mortgages and HELOCs in the event of an economic downturn.

The Bank maintained stringent underwriting standards with conservative LTV ratios. Stress testing has indicated that the Bank should be in a position to absorb reasonable losses in an economic downturn.

D. Liquidity Principle Disclosure

Asset and Liability Committee (ALCO) is a senior management-level committee that provides consultation to the CEO for making decisions in order to achieve the goals of asset and liability management that includes liquidity management. It actively monitors and controls exposures across business lines and currencies and regularly provides reports to the Board of Directors (BOD). The mandate of ALCO is dictated by the ALCO Policy that provides guidelines on liquidity management during normal and stressed situations with specific action plans and defined metrics of what constitute a normal or stressed scenarios.

Limits are an important tool used in managing liquidity risk to keep exposures within regulatory requirements and risk appetite. Limits are reviewed annually by management and approved by the BOD. Limits status are monitored and reported to the Risk Committee monthly and to the BOD quarterly for review and approval if a breach were to occur.

Liquidity Coverage Ratio (LCR) as at March 31, 2022 is 527%.

Net Cumulative Cash Flow as at March 31, 2022: Net positive cash flow monthly for the next 12 months.